Pages that link to "Q75302701"
Jump to navigation
Jump to search
The following pages link to Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1 (Q75302701):
Displaying 25 items.
- The development of immunoconjugates for targeted cancer therapy (Q27021990) (← links)
- Advances in anticancer immunotoxin therapy (Q28085551) (← links)
- Discovery of mesothelin and exploiting it as a target for immunotherapy (Q33772688) (← links)
- Mesothelin Immunotherapy for Cancer: Ready for Prime Time? (Q33816551) (← links)
- A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells (Q33995305) (← links)
- Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts (Q35023967) (← links)
- A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer (Q35230663) (← links)
- Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? (Q35237511) (← links)
- Mesothelin-targeted agents in clinical trials and in preclinical development (Q35815380) (← links)
- Immunogenicity of therapeutic recombinant immunotoxins (Q36593468) (← links)
- Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors (Q36766032) (← links)
- Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies (Q37165245) (← links)
- Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity (Q37327375) (← links)
- Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity (Q37400550) (← links)
- Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges (Q38903708) (← links)
- Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy (Q39848249) (← links)
- Sequential optimization of methotrexate encapsulation in micellar nano-networks of polyethyleneimine ionomer containing redox-sensitive cross-links (Q40697198) (← links)
- Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies (Q42939121) (← links)
- Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin (Q44424103) (← links)
- Developmental Immunotoxicology Assessment of Rituximab in Cynomolgus Monkeys (Q46176587) (← links)
- Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity (Q47222860) (← links)
- Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies. (Q49540233) (← links)
- Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression (Q58386415) (← links)
- Immunotoxins for targeted cancer therapy (Q79199423) (← links)
- Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation (Q97644522) (← links)